Virus-like Particle Vaccines and Platforms for Vaccine Development.
Virus-like Particle Vaccines and Platforms for Vaccine Development.
复制标题
DOI：
10.3390/v15051109
复制
发表时间：
2023-05-02
期刊：
影响因子：
--
通讯作者：
Tumban E
中科院分区：
文献类型：
--
作者：
Kheirvari M;Liu H;Tumban E
在过去的二十年里，病毒样颗粒（VLP）引起了人们的广泛兴趣。使用基于 VLP 的疫苗来预防三种传染原——乙型肝炎病毒、人乳头瘤病毒和戊型肝炎病毒——已获得批准；它们非常有效并提供持久的免疫反应。除此之外，来自其他病毒感染原（感染人类、动物、植物和细菌）的 VLP 也在开发中。这些 VLP，尤其是来自人类和动物病毒的 VLP，可作为独立疫苗来预防 VLP 来源的病毒。此外，VLP，包括源自植物和细菌病毒的VLP，可以作为展示来自其他传染源或代谢疾病（例如癌症）的外源肽抗原的平台，即它们可用于开发嵌合VLP。嵌合VLP的目标是增强VLP上展示的外源肽的免疫原性，而不一定是平台上的。本综述总结了已批准和正在开发的人用和兽用 VLP 疫苗。此外，本综述总结了已在临床前研究中开发和测试的嵌合 VLP 疫苗。最后，审查总结了基于 VLP 的疫苗（例如混合/嵌合 VLP）相对于传统疫苗方法（例如减毒活疫苗和灭活疫苗）的优势。
Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are very efficacious and offer long-lasting immune responses. Besides these, VLPs from other viral infectious agents (that infect humans, animals, plants, and bacteria) are under development. These VLPs, especially those from human and animal viruses, serve as stand-alone vaccines to protect against viruses from which the VLPs were derived. Additionally, VLPs, including those derived from plant and bacterial viruses, serve as platforms upon which to display foreign peptide antigens from other infectious agents or metabolic diseases such as cancer, i.e., they can be used to develop chimeric VLPs. The goal of chimeric VLPs is to enhance the immunogenicity of foreign peptides displayed on VLPs and not necessarily the platforms. This review provides a summary of VLP vaccines for human and veterinary use that have been approved and those that are under development. Furthermore, this review summarizes chimeric VLP vaccines that have been developed and tested in pre-clinical studies. Finally, the review concludes with a snapshot of the advantages of VLP-based vaccines such as hybrid/mosaic VLPs over conventional vaccine approaches such as live-attenuated and inactivated vaccines.
登录
查看更多内容
影响因子：
3.7
作者：
Hamada-Tsutsumi S;Iio E;Watanabe T;Murakami S;Isogawa M;Iijima S;Inoue T;Matsunami K;Tajiri K;Ozawa T;Kishi H;Muraguchi A;Joh T;Tanaka Y
通讯作者：
Tanaka Y
植物生产的非洲马疾病病毒样颗粒的免疫原性：对新型疫苗的影响。
影响因子：
13.8
作者：
Dennis SJ;Meyers AE;Guthrie AJ;Hitzeroth II;Rybicki EP
通讯作者：
Rybicki EP
影响因子：
7.8
作者：
Chen CW;Saubi N;Kilpeläinen A;Joseph-Munné J
通讯作者：
Joseph-Munné J
影响因子：
1.6
作者：
Choi, Yoo Ri;Kim, Hyoung Jin;Kim, Hong-Jin
通讯作者：
Kim, Hong-Jin
影响因子：
4.4
作者：
Chackerian, Bryce;Durfee, Marisa R.;Schiller, John T.
通讯作者：
Schiller, John T.